Sagimet Biosciences GAAP EPS of -$0.32 beats by $0.21

* Sagimet Biosciences press release [https://seekingalpha.com/pr/20199186-sagimet-biosciences-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:SGMT [https://seekingalpha.com/symbol/SGMT]): Q2 GAAP EPS of -$0.32 beats by $0.21.
* Cash, cash equivalents and marketable securities as of June 30, 2025 were $135.5 million.

MORE ON SAGIMET BIOSCIENCES

* Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 [https://seekingalpha.com/article/4792426-sagimet-positive-china-partner-acne-vulgaris-data-bodes-well-for-tvb-3567]
* Sagimet gains as Canaccord Genuity starts with Buy on potential against MASH [https://seekingalpha.com/news/4471525-sagimet-stock-gains-canaccord-starts-buy]
* Sagimet climbs as acne therapy hits main goals in late-stage trial in China [https://seekingalpha.com/news/4455302-sagimet-stock-climbs-acne-trial-data]
* Seeking Alpha’s Quant Rating on Sagimet Biosciences [https://seekingalpha.com/symbol/SGMT/ratings/quant-ratings]
* Historical earnings data for Sagimet Biosciences [https://seekingalpha.com/symbol/SGMT/earnings]